SCHEMBL1034838

SCHEMBL1034838

Cc1cc(-c2ccc3cccc(C(=O)Nc4cccnc4)c3n2)no1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 4/20 0.58
▸ EGLN1 Q9GZT9 1/20 0.50
▸ TP53 P04637 2/20 0.49
▸ ALDH1A1 P00352 7/20 0.48
▸ KDM4E B2RXH2 4/20 0.48
▸ MAPT P10636 3/20 0.48
▸ TSHR P16473 3/20 0.48
▸ HPGD P15428 3/20 0.48
▸ USP2 O75604 1/20 0.48
▸ GAA P10253 1/20 0.48
▸ POLB P06746 2/20 0.47
▸ NAMPT P43490 2/20 0.47
▸ HTT P42858 1/20 0.47
▸ NPC1 O15118 4/20 0.47
▸ RAB9A P51151 4/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ PKM P14618 1/20 0.47
▸ LMNA P02545 1/20 0.46
▸ ALOX12 P18054 1/20 0.46
▸ CASP1 P29466 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1031934 0.82 EGLN1 (0.60) HSD17B10EGLN1ALDH1A1KDM4EMAPT
SCHEMBL1035323 0.81 KDM4E (0.48) HSD17B10ALDH1A1KDM4EMAPTTSHR
SCHEMBL1034326 0.80 RAB9A (0.58) HSD17B10TP53ALDH1A1KDM4EMAPT
SCHEMBL1032904 0.79 HPGD (0.49) ALDH1A1KDM4EMAPTHPGDGAA
SCHEMBL1035479 0.78 PARP1 (0.45) HSD17B10ALDH1A1KDM4EMAPTTSHR
SCHEMBL29862956 0.75 EGLN1 (0.74) HSD17B10EGLN1ALDH1A1KDM4EMAPT
SCHEMBL27810270 0.75 EGLN1 (0.74) HSD17B10EGLN1ALDH1A1KDM4EMAPT
SCHEMBL1032356 0.75 CSF1R (0.54) EGLN1MAPTTSHRSMN1; SMN2LMNA
SCHEMBL1031619 0.75 SIRT2 (0.50) EGLN1ALDH1A1KDM4EMAPTTSHR
SCHEMBL1034242 0.74 ALDH1A1 (0.54) EGLN1ALDH1A1HTTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2273992-B1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2016-05-25 — — EP disclosed
EP-2273992-B1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2016-05-25 — — EP disclosed
US-20110046110-A1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2011-02-24 — — US disclosed
US-20110046110-A1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2011-02-24 — — US disclosed
US-20110046110-A1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2011-02-24 — — US disclosed
EP-2273992-A1 QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS Sirtris Pharmaceuticals, Inc. (US) 2011-01-19 — — EP disclosed
WO-2009134973-A1 QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2009-11-05 — — WO disclosed
WO-2009134973-A1 QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2009-11-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046110-A1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRT3, SIRT1, SIRT2 HSD17B10 1813/4885EGLN1 546/4885TP53 557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback